The discovery and development of pharmaceuticals for human use. See Resume, Publications, Presentations and Patents
Preclinical development, Phase I & II clinica
The preclinical and clinical development of the neuraminidase inhibitor, zanamivir, for the treatment and prophylaxis of influenza in humans. See Details of Most Recent Positions, Publications and Patents
A perspective by Reece PA entitled "Zanamivir for the treatment of avian influenza (H5N1) inf
An oral paper presentation at the Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, Scotland, 15 July 2009 entitled "Zanamivir PK/PD: implications for the treatment of avian influenza
A review by Reece PA entitle
Phillip Reece provided a range of advice on pharmaceutical development matters to the legal team involved in one of Australia's largest commercial litigation cases. This involved explaining complex scientific issues to the legal team, assisting in the preparation of questions for expert witnesses and the preparation of technical reports, chronologies and literature reviews.
Chief Executive Officer and Managing Director o
Prepare advice and technical reports on various pharmaceutical research and development projects within Phillip Reece's area of expertise to clients in the biotechnology, pharmaceutical and legal industries; attend advisory meetings, Board meetings as required by clients.
Rates are negotiable and based on the duration of the consultancy. Milest
Phillip Reece is an Honorary Senior Fellow of the Department of Pharmacology and has access to the University Library and other services but does not receive any remuneration from the University. See: University Web-site